

CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Formerly known as Albedo Limited)
(Company Registration No. 200505118M)

LOAN OF HK\$20,000,000 GRANTED TO THE COMPANY'S SUBSIDIARY

1. INTRODUCTION

The Board of Directors of China Medical (International) Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) would like to announce that the Company’s wholly owned subsidiary, CMIC Hemodialysis (Hong Kong) Limited (the “**Subsidiary**”) has on 20 June 2016 entered into a loan agreement with Concorde Global Limited (the “**Lender**”) (the “**Loan Agreement**”). Pursuant to the Loan Agreement, the Lender has agreed to grant a loan of HK\$20,000,000 (approximately S\$3,468,000) (the “**Loan**”) to the Subsidiary, subject to the terms and conditions set out in the Loan Agreement.

2. PRINCIPAL TERMS OF THE LOAN AGREEMENT

Principal Amount	HK\$20,000,000 (approximately S\$3,468,000)
Interest	The unpaid principal amount outstanding from time to time shall be subject to interest at the rate of 12.0% per annum and will be payable on the 1st day of each and every calendar month commencing from the month immediately after the month of the date of the Loan Agreement until the Loan is repaid in full.
Maturity Date	19th December 2016
Repayment and Prepayment	The Loan shall be repaid by the Subsidiary to the Lender by the Maturity Date free from any set-off and/or counterclaim. The Lender may prepay the whole or any part of the Loan by instalments without any penalty at any time.
Default in Payment	If default is made by the Subsidiary in the payment upon the due date of any sum payable to the Lender under the Loan Agreement, whether in respect of principal or interest, the Lender shall be entitled to charge simple interest on that sum from the date of the default until the sum is fully repaid (before and after judgment) at the interest rate 24.0% per annum.
Guarantee	The Loan will be secured by a corporate guarantee to be granted by the Company (the “ Corporate Guarantee ”) as well as a deed of guarantee to be granted by the Company’s substantial shareholder, Dato Dr Choo Yeow Ming (collectively

the “**Guarantees**”).

Costs and Expenses Each party shall bear its own costs, charges and expenses incurred by each party in connection with the negotiation, preparation or execution of the Loan Agreement and the Guarantees. The Subsidiary shall pay to the Lender on demand all legal fees and expenses and all other out-of-pocket costs and expenses reasonably incurred by the Lender in connection with the enforcement of any of its rights under the Loan Agreement.

Governing Law The Loan Agreement is governed by the laws of Hong Kong.

3. USE OF PROCEEDS

The Subsidiary shall use the Loan solely for the working capital of the Subsidiary.

4. INFORMATION ON THE LENDER

The Lender is a company incorporated in British Virgin Islands and is a special purpose vehicle set up to grant the Loan. None of the directors or shareholders and their respective associates of the Lender have any interest, direct or indirect, in the Company. Other than the Loan Agreement, the Lender does not have any other business dealings with the Company.

5. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

Save as disclosed in this announcement, none of the Directors or substantial shareholders and their respective associates of the Company has any interest (other than their respective shareholdings in the Company), direct or indirect, in the Loan Agreement or the Lender.

6. DOCUMENTS AVAILABLE FOR INSPECTION

A copy of the Loan Agreement and the Corporate Guarantee may be inspected at the registered office of the Company in Singapore at 1 Scotts Road, #20-03/04 Shaw Centre, Singapore 228208 during normal business hours for a period of three (3) months from the date of this announcement.

7. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the transactions set out in this announcement and the Group, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading.

Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

BY ORDER OF THE BOARD

20 June 2016

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Director, Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.